Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia | BioMed Central Journal of Hematology Oncology Open Access Review P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia Shundong Cang and Delong Liu Address Division of Hematology Oncology New York Medical College Valhalla NY 10595 USA Email Shundong Cang - cangshundong@ Delong Liu - delong_liu@ Corresponding author Published I October 2008 Received 8 July 2008 Journal of Hematology Oncology 2008 1 15 doi 1756-8722-1-15 Accepted 1 October 2008 This article is available from http content 1 1 15 2008 Cang and Liu licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Imatinib was the first BCR-ABL-targeted agent approved for the treatment of patients with chronic myeloid leukemia CML and confers significant benefit for most patients however a substantial number of patients are either initially refractory or develop resistance. Point mutations within the ABL kinase domain of the BCR-ABL fusion protein are a major underlying cause of resistance. Of the known imatinib-resistant mutations the most frequently occurring involve the ATP-binding loop P-loop . In vitro evidence has suggested that these mutations are more oncogenic with respect to other mutations and wild type BCR-ABL. Dasatinib and nilotinib have been approved for second-line treatment of patients with CML who demonstrate resistance or intolerance to imatinib. Both agents have marked activity in patients resistant to imatinib however they have differential activity against certain mutations including those of the P-loop. Data from clinical trials suggest that dasatinib may be more effective vs. nilotinib for treating patients harboring P-loop mutations. Other mutations that are .
